IRCT20210808052110N1RecruitingPhase 2
To evaluate Neoadjuvant chemotherapy followed by chemoradiation in patients with unresectable cervical cancer
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 74
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 75 years (—)
- Sex
- Female
Inclusion Criteria
- •1.Unresectable cervical cancer(IIB toIVA,IB3,IIAmore than 4cm)
- •2.No history of metastasis
- •3.Adequate renal function(GFR more than 60ml per min per1.73)
- •4.Adequate hepatic function(Liver enzyme<5* upper limit normal)
- •5.Adequate bone marrow function(Absolute neutrophil>1500)
- •6-Without history of systemic disease
- •7.Absence of active infection
- •8.Absence of previous or concurrent oncology pathology
- •9.ECOG performance status 0 and 1
- •10.Age 18 to 75 years
Exclusion Criteria
- •1-Previous pelvic radiation
- •2-Pregnancy
- •3-Serious medical illness
- •4-Hypersensitivity to chemotherapy agent
Investigators
Similar Trials
Completed
Not Applicable
Prospective study of neoadjuvant chemotherapy for HER2 positive breast cancer.JPRN-UMIN000046338Sapporo Medical University24
Recruiting
Not Applicable
Prospective study of neoadjuvant chemotherapy with FEC100x4 for BRCAness cases in triple negative breast cancerBreast cancerJPRN-UMIN000029433Tokyo medical university70
Completed
Not Applicable
Effect of neoadjuvant chemotherapy in patients with gastric cancerIRCT2015020220906N1Vice chancellor for Research and Technology30
Recruiting
Phase 3
A Phase III Trial to Investigate the Effect of NACT in Lymph Node Positive Cervix CancerCTRI/2023/08/056902Dr. Partha Sarathi Bhattacharyya
Recruiting
Not Applicable
A phase II study of Neoadjuvant chemotherapy plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage ovarian cancer (TRU-D)NeoplasmsKCT0003742Yonsei University Health System, Severance Hospital24